We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Anavex Life Sciences Corporation | NASDAQ:AVXL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.47% | 3.44 | 3.38 | 3.84 | 3.48 | 3.37 | 3.40 | 949,972 | 00:48:08 |
Financial Highlights:
“We are entering the second half of 2017 with our strongest balance sheet to date, which allows the Company to execute the Phase 2 clinical trial in Rett syndrome, for which ANAVEX™ 2-73 has been granted Orphan Drug Designation by the FDA, as well as the Phase 2/3 clinical trial in Alzheimer’s disease and the Phase 2 clinical trial in Parkinson’s disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex Life Sciences. “We look forward to initiating these placebo-controlled clinical trials. The respective trial designs are based on broad genomic and biomarker characterization, pharmacokinetic and pharmacodynamic modeling including data from patients in previous ANAVEX™ 2-73 trials, as well as preclinical translational science. To our knowledge, this is the first use of this approach in the design of clinical trials for Alzheimer’s disease, Parkinson’s disease and Rett syndrome, and marks a shift towards advancing implementation of precision medicine for these and other neurodegenerative and neurodevelopmental diseases."
Corporate Highlights:
• July 20, 2017 – Anavex further strengthened its Scientific Advisory Board with the appointment of Andrew J. Cole, M.D., F.R.C.P.(C.) Dr. Cole is Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical School.
• May 22, 2017 – Anavex announced new preclinical data for ANAVEXTM 2-73 in the rare diseases Angelman syndrome, Fragile X syndrome and Rett syndrome.
Planned Objectives:
The financial information for the three and nine months ended June 30, 2017, should be read in conjunction with the Company’s condensed consolidated interim financial statements, which will appear on EDGAR and will be available on the Anavex website at www.anavex.com.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEXTM 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEXTM 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEXTM 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEXTM 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
ANAVEX LIFE SCIENCES CORP. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited) | ||||||||
June 30, | September 30, | |||||||
ASSETS | 2017 | 2016 | ||||||
Current | ||||||||
Cash | $ | 24,793,424 | $ | 9,186,814 | ||||
Sales Tax Recoverable | 8,216 | 79,347 | ||||||
Prepaid expenses and deposits | 52,694 | 180,124 | ||||||
Total current assets | 24,854,334 | 9,446,285 | ||||||
Deposits | 52,396 | 52,396 | ||||||
Total assets | $ | 24,906,730 | $ | 9,498,681 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current | ||||||||
Accounts payable and accrued liabilities | $ | 1,435,498 | $ | 3,119,993 | ||||
Deferred grant income | 19,073 | 70,532 | ||||||
Total liabilities | 1,454,571 | 3,190,525 | ||||||
Common stock | 42,173 | 36,169 | ||||||
Additional paid-in capital | 109,733,970 | 84,290,140 | ||||||
Accumulated deficit | (86,323,984 | ) | (78,018,153 | ) | ||||
Total stockholders' equity | 23,452,159 | 6,308,156 | ||||||
Total liabilities and stockholders' equity | $ | 24,906,730 | $ | 9,498,681 | ||||
ANAVEX LIFE SCIENCES CORP. | |||||||
CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS | |||||||
THREE MONTHS ENDED JUNE 30, 2017 AND 2016 | |||||||
(Unaudited) | |||||||
2017 | 2016 | ||||||
Operating Expenses | |||||||
General and administrative | $ | 1,405,026 | $ | 1,134,845 | |||
Research and development | 2,300,277 | 1,158,820 | |||||
Total operating expenses | 3,705,303 | 2,293,665 | |||||
Operating Loss | (3,705,303 | ) | (2,293,665 | ) | |||
Other income (expenses) | |||||||
Grant income | 69,146 | 47,767 | |||||
Gain on settlement of accounts payable | 75,204 | - | |||||
Interest income, net | 26,677 | 2,626 | |||||
Financing related charges and adjustments | (8 | ) | |||||
Foreign exchange gain (loss) | (65,932 | ) | 8,924 | ||||
Total other income (expenses) | 105,095 | 59,309 | |||||
Net loss before income taxes | (3,600,208 | ) | (2,234,356 | ) | |||
Income tax expense - current | (9,877 | ) | (6,000 | ) | |||
Net loss | $ | (3,610,085 | ) | $ | (2,240,356 | ) | |
Net loss per Share | |||||||
Basic and Diluted | $ | (0.09 | ) | $ | (0.06 | ) | |
Weighted Average Number of Shares Outstanding | |||||||
Basic and Diluted | 41,509,225 | 35,709,686 | |||||
ANAVEX LIFE SCIENCES CORP. | |||||||
CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS | |||||||
NINE MONTHS ENDED JUNE 30, 2017 AND 2016 | |||||||
(Unaudited) | |||||||
2017 | 2016 | ||||||
Operating Expenses | |||||||
General and administrative | $ | 3,647,224 | $ | 5,117,591 | |||
Research and development | 6,835,700 | 3,888,676 | |||||
Total operating expenses | 10,482,924 | 9,006,267 | |||||
Operating Loss | (10,482,924 | ) | (9,006,267 | ) | |||
Other income (expenses) | |||||||
Grant income | 121,116 | 113,701 | |||||
Research and development incentive income | 2,022,902 | 571,093 | |||||
Gain on settlement of accounts payable | 75,204 | 151,402 | |||||
Interest income, net | 48,479 | 6,832 | |||||
Financing related charges and adjustments | - | (1,175 | ) | ||||
Foreign exchange gain (loss) | (40,128 | ) | (37,637 | ) | |||
Total other income | 2,227,573 | 804,216 | |||||
Net loss before income taxes | (8,255,351 | ) | (8,202,051 | ) | |||
Income tax expense - current | (50,480 | ) | (23,615 | ) | |||
Net loss | $ | (8,305,831 | ) | $ | (8,225,666 | ) | |
Net loss per Share | |||||||
Basic and Diluted | $ | (0.21 | ) | $ | (0.24 | ) | |
Weighted Average Number of Shares Outstanding | |||||||
Basic and Diluted | 40,344,149 | 34,961,838 | |||||
For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media: Dennis Dobson, Jr. Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com Social Media: Bill Douglass Gotham Communications, LLC 646-504-0890 bill@gothamcomm.com
1 Year Anavex Life Sciences Chart |
1 Month Anavex Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions